Literature DB >> 27090014

Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.

Jun-Hai Tang1, Zhi-Xiong Ma2, Guo-Hao Huang1, Qing-Fu Xu1, Yan Xiang1, Ningning Li3, Kastytis Sidlauskas3, Eric Erquan Zhang2, Sheng-Qing Lv4.   

Abstract

PURPOSE: The aim of this study was to investigate the effect of downregulation of HIF-1α gene on human U251 glioma cells and examine the consequent changes of TMZ induced effects and explore the molecular mechanisms.
METHODS: U251 cell line stably expressing HIF-1α shRNA was acquired via lentiviral vector transfection. The mRNA and protein expression alterations of genes involved in our study were determined respectively by qRT-PCR and Western blot. Cell proliferation was measured by MTT assay and colony formation assay, cell invasion/migration capacity was determined by transwell invasion assay/wound healing assay, and cell apoptosis was detected by flow cytometry.
RESULTS: We successfully established a U251 cell line with highly efficient HIF-1α knockdown. HIF-1a downregulation sensitized U251 cells to TMZ treatment and enhanced the proliferation-inhibiting, invasion/migration-suppressing, apoptosis-inducing and differentiation-promoting effects exerted by TMZ. The related molecular mechanisms demonstrated that expression of O(6)-methylguanine DNA methyltransferase gene (MGMT) and genes of Notch1 pathway were significantly upregulated by TMZ treatment. However, this upregulation was abrogated by HIF-1α knockdown. We further confirmed important regulatory roles of HIF-1α in the expression of MGMT and activation of Notch1 pathways.
CONCLUSION: HIF-1α downregulation sensitizes U251 glioma cells to the temozolomide treatment via inhibiting MGMT expression and Notch1 pathway activation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain glioma; Drug resistance; HIF-1α; Notch1 pathway; O(6)-methylguanine DNA methyltransferase (MGMT); Temozolomide

Mesh:

Substances:

Year:  2016        PMID: 27090014     DOI: 10.1016/j.yexcr.2016.04.011

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  12 in total

1.  Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide-induced autophagic death of U251 glioma cells.

Authors:  Bing Li; Chun Zhou; Liang Yi; Lunshan Xu; Minhui Xu
Journal:  Oncol Lett       Date:  2017-12-06       Impact factor: 2.967

2.  miR-138-5p Inhibits Vascular Mimicry by Targeting the HIF-1α/VEGFA Pathway in Hepatocellular Carcinoma.

Authors:  Hongwei Liu; Tao Tang; Xiujin Hu; Weihe Tan; Peng Zhou; Huixian Zhang; Yanmei Liu; Chen Chen; Meng Yang; Meifang Zhou; Shuxia Xuan; Bin Cheng; Weiguo Yin; Jinduan Lin
Journal:  J Immunol Res       Date:  2022-05-28       Impact factor: 4.493

3.  Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.

Authors:  Danhua Zhu; Ming Tu; Bo Zeng; Lin Cai; Weiming Zheng; Zhipeng Su; Zhengquan Yu
Journal:  Cancer Med       Date:  2017-01-08       Impact factor: 4.452

4.  OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth.

Authors:  Rheal A Towner; Nataliya Smith; Debra Saunders; Chase A Brown; Xue Cai; Jadith Ziegler; Samantha Mallory; Mikhail G Dozmorov; Patricia Coutinho De Souza; Graham Wiley; Kyeongsoon Kim; Shinwook Kang; Doo-Sik Kong; Young-Tae Kim; Kar-Ming Fung; Jonathan D Wren; James Battiste
Journal:  Transl Oncol       Date:  2018-11-20       Impact factor: 4.243

5.  Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy.

Authors:  Xiudong Guan; Md Nabiul Hasan; Gulnaz Begum; Gary Kohanbash; Karen E Carney; Victoria M Pigott; Anders I Persson; Maria G Castro; Wang Jia; Dandan Sun
Journal:  Cell Death Dis       Date:  2018-09-27       Impact factor: 8.469

Review 6.  Hypoxia: The Cornerstone of Glioblastoma.

Authors:  Marta Domènech; Ainhoa Hernández; Andrea Plaja; Eva Martínez-Balibrea; Carmen Balañà
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

7.  Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide.

Authors:  Alessia Lo Dico; Cristina Martelli; Cecilia Diceglie; Giovanni Lucignani; Luisa Ottobrini
Journal:  Front Oncol       Date:  2018-07-02       Impact factor: 6.244

8.  FM19G11 inhibits O6 -methylguanine DNA-methyltransferase expression under both hypoxic and normoxic conditions.

Authors:  Chao-Guo You; Han-Song Sheng; Chao-Ran Xie; Nu Zhang; Xue-Sheng Zheng
Journal:  Cancer Med       Date:  2018-05-15       Impact factor: 4.452

9.  The HIF1α/HIF2α-miR210-3p network regulates glioblastoma cell proliferation, dedifferentiation and chemoresistance through EGF under hypoxic conditions.

Authors:  Pan Wang; Qian Yan; Bin Liao; Lu Zhao; Shuanglong Xiong; Junwei Wang; Dewei Zou; Jinyu Pan; Liangqi Wu; Yangmin Deng; Nan Wu; Sheng Gong
Journal:  Cell Death Dis       Date:  2020-11-18       Impact factor: 8.469

Review 10.  Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Smart Drug Delivery Systems in the Treatment of Glioblastoma Multiforme.

Authors:  Raneem Jnaidi; António José Almeida; Lídia M Gonçalves
Journal:  Pharmaceutics       Date:  2020-09-10       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.